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Abstract 
The attachment and penetration of epithelial cells by Mycobacterium avium subsp. 
paratuberculosis (MAP) requires a bacterial fibronectin (FN) attachment protein FAP-P, 
which facilitates binding of FN by MAP. The region of FAP-P that interacts with FN is 
known, however, the region of FN that is bound by FAP-P is to be determined. 
Identification of the region of FN to which FAP-P binds would enable the synthesis of a 
competing peptide that could prevent FN binding by MAP. The first step toward locating 
this binding site is the design of a reliable FN binding assay.  The purpose of this 
investigation was to determine the optimal conditions (time, temperature, probe 
concentration, specificity, and color of assay plates) necessary for sensitive, specific 
binding of FN by FAP-P. Biotinylated peptides representing the FN binding domain of 
FAP-P and a control peptide were used as probes in a chemiluminescence assay to 
evaluate the binding of FAP-P to FN. The FAP-P probe bound specifically to FN when 
probes were incubated for 30 minutes at 37oC in black 96-well microtiter plates. A 10-
fold increase in specific FN binding by the FAP-P probe resulted when incubation was 
increased from 30 minutes to 60 minutes in combination with the use of white microtiter 
plates over black microtiter plates. A dose dependent binding of FN by the FAP-P probe was 
observed with increasing probe concentrations (1.0 µg FAP-P, 2.0 µg FAP-P, and 4.0 µg 
 
 
 
 
FAP-P) using optimized conditions. The assay thus described can be used to locate the 
FAP-P binding site on FN in protease-generated FN fragments. This, in turn will enable 
the design of peptides that could be incorporated into calf management programs that 
could block FN binding by MAP and reduce the reduce the incidence of Johne’s disease. 
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Chapter 1: Literature Review 
1.1 Johne’s Disease 
 1.1.1 Overview 
 Johne’s disease is a chronic, usually fatal intestinal disease that primarily affects 
dairy cattle in the US (1). It is caused by Mycobacterium avium subsp. paratuberculosis 
(MAP), which is transmitted by the fecal-oral route (2). The pathogenesis of MAP begins 
after ingestion and passage through the duodenum, where the organism gets opsonized by 
fibronectin (FN), a glycoprotein present in bile (3). The MAP-FN complex then travels 
further down the intestinal tract to the ileum. The epithelial layer of the ileum contains 
cells known as M cells, which express receptor proteins known as integrins. Integrin 
receptors bind FN-opsonized MAP and mediate phagocytosis of MAP by these M cells 
(4, 5). Although there are several FN binding proteins expressed by MAP, the FN 
attachment protein (FAP) has been shown to be critical for attachment and penetration of 
M cells by MAP. These M cells convey MAP to macrophages. Once inside a 
macrophage, MAP inhibits fusion of the phagosome with the lysosomes. This enables 
MAP to persist and replicate within phagocytic cells (2).  
 MAP is a very slow-growing organism, so the progression of this disease is 
likewise very slow (3). It can take two to five years before an infected animal develops 
clinical disease (1). Diagnostic tests are reliable only when the animals have progressed 
to the clinical stage of disease. Consequently, Johne’s disease results in annual losses of 
as much as $1 billion to the US cattle industry (6). 
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 The region of FAP to which FN binds has been identified in a closely related 
subspecies, Mycobacterium avium subsp. hominissuis, was found to be located within 
amino acid residues 269-292. The corresponding sequence in FAP-P is identical. 
However, where the FAP-P peptide binds on FN is not yet known (7). It has been 
reported that FAP binds to a region near the carboxyl terminus (C-terminus) of the FN 
monomer, but empirical evidence supporting this conclusion have not yet been published 
(7). 
 In this investigation, we propose to optimize the binding between FAP-P and FN 
in a microplate assay. The successful outcome of this investigation will allow future 
studies that identify the region of FN that is recognized and bound by FAP-P. This in turn 
will enable the design of peptides that could be incorporated into calf management 
programs, which could work by acting as competitors with MAP for FN and reduce the 
probability of MAP infection. This model could also provide insight into the mechanisms 
underlying the manifestation of Crohn’s disease, a human gastrointestinal inflammatory 
disease that has been attributed to MAP (8). 
1.1.2 History 
Johne’s disease was first described in 1895 by Johne and Frothingham, who 
described the presence of acid-fast bacilli in infected cattle intestines. The disease was 
called pseudo-tuberculous by Bang in 1902, as it was indistinguishable from a form of 
tuberculosis.  By 1908, the disease was reported in the United States, Belgium, 
Switzerland, Holland, France, Denmark, Germany, and Norway. It wasn’t until 1910 that 
when the disease was called paratuberculosis or Johne’s disease, after the causative 
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organism was isolated by Twort and called Mycobacterium enteriditis chronicae 
pseudotuberculosae bovis johne. Nowadays, Johne’s disease has been reported on every 
continent except Antarctica, threatening the ruminant agriculture worldwide (9). 
1.1.3 Economic impact 
Johne’s disease, or paratuberculosis, is a serious burden on the world dairy 
industry (9, 10). Economic losses in the dairy industry from paratuberculosis is a result of 
reduced milk production, premature culling and body-weight losses in cattle slaughter 
(11). In US dairies, financial losses associated with MAP occurs across all herd sizes and 
regions. Lost milk production and higher net cow-replacement costs contributed to 
decreased value of production per cow inventory in herds with Johne’s disease (11). 
When economic losses became substantial, farmers with paratuberculosis-positive herds 
were encouraged to participate in Johne’s disease control programs and farmers with 
paratuberculosis-negative herds were motivated to devise biosecurity programs to keep 
MAP from entering their herds (11). In the US dairy industry, Johne’s disease is 
estimated to cost US$22 to US$27 per cow annually in lost revenue and increase cow 
replacement costs (11). 
 1.1.4 Stages and symptoms 
 Johne’s disease is characterized as a chronic, granulomatous enteritis caused by 
ingestion of food, water, milk, or colostrum, contaminated with MAP (1). Infected 
animals progress through three stages: asymptomatic, clinical, and advanced clinical 
stages (12). Initial infection of cattle usually occurs within the first weeks of life. 
Although signs are not typically observed before 2 years of age, younger cattle may shed 
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viable MAP cells in feces. The clinical stage falls in a period of 2 to 10 years old. At this 
stage, infected cattle experience poor nutrient absorption, weight loss, increased thirst, 
and poor milk production (6). Pathology of the small intestine demonstrates that at this 
stage, the intestinal wall becomes thickened and tissue changes is characterized by the 
formation of submucosal granulomas (1). If not culled from the herd, cattle progress into 
an advanced clinical stage where they present with diarrhea, and a general wasting 
syndrome in which they become anemic, lethargic, emaciated, and too weak to stand (1, 
12).  
1.2 Management of Johne’s disease 
Diagnosis of Johne’s disease involves detection of MAP, the causative agent, or 
the identification of an immunological response against MAP. A combination of 
diagnostic tests and quantitative interpretation of test results provide vital tools for 
diagnosing Johne’s disease. Diagnostic tests helpful in diagnosing Johne’s disease 
include fecal smears, fecal and tissue culture, and enzyme-linked immunosorbent assay 
(ELISA) (9). 
1.2.1 Culture 
The gold standard for primary isolation of mycobacteria requires a combination of 
solid and liquid media with a recommended minimum turnaround time of about 12 weeks 
after specimen collection to identify mycobacterial species. Meeting these requirements 
of culture test systems have proven challenging. In addition, the stage of the disease at 
the time of specimen collection can influence the sensitivity to detect MAP in fecal 
culture. To culture using a solid media, the standard media used is the Herrold’s egg yolk 
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media (HEY) containing mycobactin J (MJ) (HEYMJ) (13). Colonies become detectable 
4-16 weeks after inoculation on the solid medium and may require a subculture step for 
conclusive identification (13). Utilizing liquid media is faster and more sensitive but the 
methodology is arduous as scientists must visually inspect culture vials as they handle the 
samples (14). Successful detection and culture of MAP from animal tissues, milk, breast 
milk and gut tissues of Crohn’s disease patients have been accomplished using the 
nonradiometric BACTEC Mycobacteria Growth Indicator Tube (MGIT) 960 system (15). 
Nevertheless, accurate diagnosis of paratuberculosis is dependent on the long 
incubation period of the organism (16). Cattle are known to be most susceptible to MAP 
infections between 0-4 months (16). Clinical disease is most frequently observed in cattle 
2-5 years of age (16). A T helper type 1 (TH1) dominated response controls MAP and 
viable cells can still be shed in small numbers, which may result in a positive fecal 
culture test result. Later during infection, the T helper type 2 (TH2) response as indicated 
by the presence of anti-MAP antibodies in serum predominates (16). The variation of 
time in bacterial shedding and antibody responses is speculated to be a result of the 
variation of infective dose with MAP infections and thus, results in variation in time of 
the occurrence of positive fecal culture test and positive ELISA tests (16). For accurate 
MAP diagnosis, scientists should consider the stage of infection of MAP (16). For 
example, in using an antibody ELISA, the probability of detecting infected cows 2 years 
of age has been estimated to be 0.06 while the same probability for cows 5 years of age 
was 0.50 (16, 17). 
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1.3 Link to Crohn’s disease 
 Crohn’s disease (CD) is a chronic inflammatory gastrointestinal tract disease in 
humans with similar pathological changes and symptoms as Johne’s disease in cattle, 
however, with unknown etiology (18–21). Along with ulcerative colitis, they are both 
classified as idiopathic inflammatory bowel diseases (IBDs) (20). In western countries, 
both IBDs display a prevalence of about 150-200 cases per 100,000 persons (20). 
Previous studies have identified CD as a disorder in genetically predisposed hosts 
resulting from the effects of environmental factors (20). In the search for IBD-
susceptibility genes, genomic investigations have identified several loci for CD in the 
pericentromeric region of chromosome 16 (identified as IBD1) (20). 
 In 1913, Dalziel reported similarities of CD, Johne’s disease, and intestinal 
tuberculosis (22). Because of this, much attention since then has been focused on a 
mycobacterial cause of CD, specifically MAP (18, 21). Some data suggest that MAP 
survives during pasteurization of contaminated milk and dairy products and may pass 
onto humans during consumption (23–25). However, in recent years, the notion that the 
causative agent of CD is MAP has been inconsistent (19, 21). The fastidious nature and 
slow-growing characteristics of MAP have made it challenging to culture and identify the 
organism from CD patients (18, 21). Differences in microbiological methodologies have 
also made it difficult to identify MAP (18, 21). In the past, MAP DNA and viable MAP 
have not been differentiated by polymerase chain reaction (PCR) (21). However, with 
improved technology and methodologies, researchers have been able to differentiate 
MAP by PCR by amplifying the insertion sequence of IS900; however, this has not 
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resolved the controversy (18), as several groups have produced conflicting results using 
PCR. Some have identified MAP by PCR only from some CD patients, whereas other 
have found MAP PCR products in all patient populations including controls. These 
differences may be due to differences in the source of MAP, as this organism can be 
cultured from peripheral blood from patients with CD, breastmilk, and intestinal lymph 
nodes (21). The possibility also exits that some of these results may have arisen from 
PCR contamination. 
1.4 Mycobacterium avium subspecies paratuberculosis (MAP) 
 1.4.1 Classification 
  The genus Mycobacterium belongs to the group Mycobacteria which are Gram 
positive microorganisms with high GC content (3). They are characterized as a small 
(0.5×1.5 micron), aerobic, acid-fast, lipid-rich cell wall, bacillus (3, 9). These bacilli are 
arranged in clumps intertwined by intercellular filaments (9). On artificial media, MAP 
can be observed as small, glistening, white, rough-smooth colonies (9). Some strains 
isolated from sheep have been reported to express orange and yellow pigments (9). In 
addition, lightly-acid-fast and non-acid-fast strains have been observed, which fail to 
absorb the Ziehl-Neelsen stain. Most can be considered saprophytic; however, they can 
cause opportunistic infections in immunocompromised persons such as respiratory 
infections. The growth rate of Mycobacterium species correlated loosely with their 
pathogenic potential. Non-pathogenic members obtain a faster growth rate, whereas 
pathogenic members obtain a slower growth with generation times nearing 24 hours (3). 
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 The main pathogens of this genus include Mycobacterium tuberculosis, 
Mycobacterium leprae, Mycobacterium bovis and the Mycobacterium avium complex 
(MAC). Members of the MAC are classified as acid-fast, slow-growing bacilli that 
produce a yellow pigment in the absence of light exposure. They are also opportunistic 
pathogens known to cause diseases in animals and humans in addition to Crohn’s disease 
(26). Brennan et al demonstrated that the MAC serotype antigens have a common 
lipopeptidyl-O-methyl rhamnose linked to an oligosaccharide; serologic specificity was 
granted by the specific oligosaccharide residues of the C-mycoside glycopeptidolipids 
(GLPs), integral constituents of the cell wall and envelope (26, 27). In the past, the MAC 
included Mycobacterium avium, Mycobacterium intracellulare and Mycobacterium 
scrofulaceum forming a serological complex of 31 serotypes of the three species (26). 
However, current literature does not include M. scrofulaceum in the complex due 
improvements in mycobacterial systematics and the distinction between M. avium and M. 
intracellulare (26). Based on nucleic acid studies and phenotypic characteristics, Thorel 
et al, proposed three subspecies of M. avium which include M. avium subsp. avium, M. 
avium subsp. paratuberculosis and M. avium subsp. silvaticum (28).  
 Mycobacterium avium subspecies paratuberculosis (MAP) is the causative agent 
of Johne’s disease in ruminants and has also been linked to Crohn’s disease in humans. 
MAP is classified by its generation time, which ranges from 12 hours-24 hours and 
requires mycobactin, a siderophore (an iron-chelating agent produced by 
microorganisms) for growth in culture (3, 9). 
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1.4.2 Genome 
  In collaboration, the National Animal Disease Center (NADC) and the University 
of Minnesota have sequenced the MAP genome (3, 29). MAP K-10, the sequenced strain, 
was obtained from a cow with Johne’s disease (3). When MAP K-10 was infected by 
phage, transformation with plasmid DNA occurred with higher efficiency than that of 
uninfected MAP K-10 (3).  
 MAP isolates can be broadly classified into two host-associated types based on 
their genome analysis and culture characteristic (15, 30): cattle isolates (called C type or 
Type II) and sheep isolates (called S type or Type I). Both strains are highly similar 
genetically, and therefore difficult to distinguish (15) Researchers have discovered a third 
strain called Type III or intermediate, which is a subtype of Type I isolates. Using the 
IS1311 insertion sequence, a single nucleotide polymorphism analysis has differentiated 
three strain types: S, C, and B (also known as Type III); however, this analysis cannot 
distinguish between Type I and Type III (15). Even though there is a host preference for 
type S, C or B strains, MAP strains have been observed to cross species and can be 
isolated from a wide range of animal species including non-ruminants (15). Since the 
publication of the complete annotated genome sequence of bovine isolate MAP K-10, 
additional MAP isolates have been sequenced. Results suggest that the bovine isolate 
MAP K-10 and human isolates are more similar as they contain deletions in the open 
reading frames (ORFs) MAP1432 through MAP1438c, whereas the sheep isolates do not 
(15). 
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1.4.3 Immunology of MAP 
In the asymptomatic and subclinical phases of Johne’s disease, MAP-infected 
cattle develop pro-inflammatory and cytotoxic immune responses associated with Type 1 
helper T cells (TH1) (31). This TH1 immune response is replaced by the Type 2 helper T 
cells (TH2)/humoral immune response as the disease advances into the clinical stages 
(31). At this stage, infected macrophages can be observed within MAP-infected tissues 
causing extensive inflammation due to the production of IL-1 (31).  
In the ileum of MAP infected cattle, severe lesions demonstrated TH2 
predominance and a decrease in regulatory T cells (Treg) gene (FOXP3) expression as 
compared to healthy cows (31). In contrast, mild ileal lesions display increased 
TH1responses, and Treg gene expression (31). Conversely, in the mesenteric lymph nodes, 
expression of FOXP3 is increased with increased lesion severity (31). Within ileal 
lesions, the change in cytokine profile due to MAP infection leads to a shift in T helper 
response from TH1 to TH2. MAP infection can no longer be controlled, as the anti-MAP 
antibodies produced (resulting from the switch from TH1 to TH2) are ineffective against 
intracellular MAP. This leads to the development of clinical Johne’s disease (31).  
In the peripheral blood mononuclear cells (PBMCs), intestinal lesions, and 
mesenteric lymph nodes of MAP-infected cattle, proinflammatory cytokine gene 
expression has shown to be altered relative to uninfected cattle (32). PBMCs from sub-
clinically infected cattle were seen to have increased expression of IL-10 (32). In MAP-
infected ileal tissue, expression of IFN-γ, TGF-, IL-5, and IL-8 genes was greater and 
IL-16 expression was lower than in the same tissues in uninfected cattle (32). MAP 
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infected mesenteric lymph node draining sites demonstrated increased IL-1α, IL-8, IL-2 
and IL-10 gene expression whereas TGF-β and IL-16 gene expression was lower (32). 
M cells are known as an avenue for antigen access in the initiation of protective 
immunity. Research has shown that they are capable of engulfing particles from the 
intestinal lumen to transport them through the epithelial layer into lymphoid tissue (33). 
MAP has been observed to enter the intestine through M cells located in the epithelium 
covering Peyer’s patches in the ileum of ruminants (7). The continuous Peyer’s patch in 
bovine ileum is a primary lymphoid tissue where B cells develop (33, 34). However, in 
the bovine upper jejunum are discrete Peyer’s patches that are secondary lymphoid tissue 
that provide adaptive immunity after antigen exposure (33).  
Interactions between FAP and FN have been shown to be crucial in the 
attachment and internalization of MAP, M. bovis BCG and M. leprae to epithelial cells, 
in vitro (7). The host cell receptors for FN-opsonized mycobacteria in vitro have been 
identified as β1 integrins. M cells display β1 integrins at high density on their luminal 
surface, making them unique amongst cells of the intestinal epithelium. Thus, the 
interaction between cell surface integrins and FN bound by organisms may explain why 
M cells are the portals of entry for MAP (7). Research suggests that bovine ileal M cells 
take up MAP cells and expel them into the sub/intraepithelial portion of Peyer’s patch 
where they’re phagocytosed by macrophages (33). Once in the phagocyte, MAP have 
been observed to evade host immune response by preventing phagosome-lysosome fusion 
and allowing MAP to survive and proliferate within macrophages. 
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1.4.4 Survival   
MAP can survive outside the host for long periods and as such can live on and 
spread in grassland environments (35). It requires about 6 months to a year to eradicate 
MAP from pasture after infection (35). Published data from an experiment  conducted on 
livestock in the northern hemisphere have demonstrated that MAP cells remain viable in 
the environment over a long time except in silage (grass compacted and stored in airtight 
compartments) with low pH or high ammonia levels or in animal house slurry (semiliquid 
mixture of manure) with urine present (35). 
1.4.5 Host species 
Although observed as a disease in domestic cattle, sheep, and goats, all ruminants 
have fallen victim to Johne’s disease as illustrated in Table 1.1 (9, 15). In addition, 
wildlife, and exotic ruminants (deer and boar) and non-ruminants such as fox, crow, 
wood mouse, badger, rabbit have been recognized to be infected with MAP (12). 
Monogastric organisms have been observed to be infected with MAP under experimental 
circumstances (9). Through the use of heavy inocula, horses, chickens, and hogs can be 
infected; however, the development of clinical disease does not follow (9). Rats, mice, 
chickens, chicken embryos, pigeons, guinea pigs, hamsters, cats, and rabbits have been 
used as experimental models to demonstrate aspects of MAP pathobiology such as  
attachment and invasion of epithelial tissues (9).  
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1.5 Fibronectin Attachment Protein (FAP)  
 Fibronectin attachment proteins (FAPs) are a family of homologous fibronectin 
(FN)-binding glycoproteins that are expressed by several mycobacteria (5, 7, 36–38). 
Previous research has identified FAPs from different mycobacteria species using 
polyclonal antibodies to a 50 kDa purified Mycobacterium vaccae FAP (FAP-V) (5, 38, 
39). These FAPs include Mycobacterium leprae (FAP-L), Mycobacterium avium (FAP-
A), Mycobacterium bovis BCG (FAP-B) and Mycobacterium smegmatis (FAP-S) (38). 
FAPs have been shown to be exposed on the bacterial cell surface of Mycobacterium 
avium complex (MAC) and Mycobacterium tuberculosis (5, 38, 40–42).The recognized 
FAPs have been cloned and characterized (38). Two non-contiguous FN binding regions 
Table 1.1: Domestic and wild animals observed to be infected with MAP, either natural, 
experimental or both. 
HOST DOMESTIC (D) 
OR WILD (W) 
REFERENCES NATURAL (N), 
EXPERIMENTAL 
(E) OR BOTH (B) 
Cattle D (15, 30) B 
Sheep D (15, 30) B 
Goats D (15, 30) B 
Red Deer W (15, 30, 66, 67) N 
Fallow Deer W (15, 30) B 
Bison W (15, 30) N 
Wild Boar W (15, 30) N 
White Rabbits W (66, 67) N 
White-Tailed 
Deer 
W (66, 67) N 
Exotic Deer W (66, 67) N 
Tule Elk W (66, 67) N 
Bighorn Sheep W (66, 67) N 
Roe Deer W (66, 67) N 
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(amino acids 177-201 (FAP-A-(177-201)) and amino acids 269-292 (FAP-A-(269-292))) 
were observed to possess highly conserved FN binding activity using recombinant FAP-
A and FAP-A peptides (5, 38). With the exception of FAP-S, both amino acid sequences 
are highly conserved among all identified FAP proteins (5, 38). 
 Through in vivo and ex vivo studies, Middleton et al and Zhao et al determined 
that the attachment of Mycobacterium bovis BCG and Mycobacterium avium subsp. 
avium to tissues was reliant on the expression of FAP (37, 40, 43). Furthermore, Kuroda 
et al, and Schorey et al, proved that cultured epithelial cells were able to endocytose 
Mycobacterium bovis BCG and Mycobacterium leprae in a FAP dependent method (37, 
39, 44). 
 The region of FAP that is required for FN binding by FAP-A-(amino acid 
residues 269-292), has been shown to block the attachment of all mycobacteria tested (M. 
bovis BCG, M. smegmatis, and M. avium) to FN-coated surfaces and to evade FN-
opsonized mycobacterial attachment to Schwann cells and epithelial cells in in vitro 
studies (5, 38). Zhao et al used alanine substitutions in synthetic FAP-A peptides as well 
as site-directed mutagenesis of recombinant FAP-A protein to identify a  four amino acid 
sequence in FAP-A-(269-292), arginine-tryptophan-phenylalanine-valine (RWFV) 
necessary for FAP dependent fibronectin binding (38).  
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MAP possesses a FAP, designated FAP-P, which mediates soluble FN binding (7, 37). 
Unlike the other mycobacterial FAPs, FAP-P is not on the surface of MAP; thus, the way 
FAP-P interacts with FN may isolate the cell binding domain from host cell receptors. 
Secott et al determined that the attachment and endocytosis of MAP by epithelial cells are 
FN-dependent processes (37).  
1.6 Fibronectin  
 Fibronectin (FN) is a 420-kDa glycoprotein that is extensively distributed in 
mammals (3, 45, 46). Based on amino acid sequence homology, FN is constituted from 
repeating structural units designated type I, type II, and type III modules as depicted in 
Figure 1.2. Each module is numbered from the N-terminus of FN and contains several 
functional domains (46). Fibronectin is found in bodily fluids such as cerebrospinal fluid, 
plasma and amniotic fluid as a soluble dimer protomer that consists of two subunits 
 
 
 
Figure 1.2: Model of the structure of fibronectin based on a previous study (48). This model shows 
the internally homologous modules termed type I, II and II. Fibronectin binding domains are indicated 
at the top of the image.  
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bound by disulfide bridges at the C-termini, and as a polymeric fibrillar network 
(insoluble form) in the extracellular matrix (ECM) and basement membrane (45, 47).  
 Fibronectin is a ligand for many cell types such as phagocytic cells and epithelial 
cells, and is known to interact with macromolecules such as integrins, collagen, fibrin, 
heparin, actin, gelatin, and complement protein 1 (C1q), sphingolipids, and DNA by 
integrin surface receptors (3, 45–48). Integrins are known to be involved in cell-cell and 
cell-extracellular matrix interactions (45).  
 Fibronectin and integrin interactions are involved in several biological processes 
such phagocytosis, metastasis, tumor formation, wound healing, lymphocyte 
recirculation, host cell activation, host cell migration, and microbial pathogenesis (45, 46, 
48).  
 Previous research has demonstrated that whole FN molecules may sometimes 
have different biological functions than FN fragments (48). Experimentally defined FN 
fragments were confirmed to be involved in increasing the expression of tumor necrosis 
factor α, collagenase, TIMP-1, urokinase-type plasminogen activator and stromelysin 
(49–51). Some fragments established potent inhibition of endothelial cell growth and 
transformation-promoting activity (52, 53). Native FN, however, did not possess the 
above functions (48). 
 At the beginning of an infection, the ability of a bacteria to bind FN-coated 
surfaces is an important mechanism for the early stage of invasion and colonization of 
host tissues (47). In a previous study, it was demonstrated that in vitro binding of M. 
bovis (BCG) to FN-coated surfaces occurred in a dose-dependent manner with purified 
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fibronectin (54). As such, we sought to determine a dose effect of our test peptide to FN-
coated wells instead of using intact organisms as mentioned above.  
1.7 Goal/Rationale 
The goal of this project was to optimize the in vitro binding of FAP-P to FN under 
several conditions (time, temperature, probe concentrations, type of microtiter 96-well 
plate and type of coating protein) to enable the identification of the region of FN 
recognized by FAP-P.  
Chapter 2: Materials and methods 
2.1 Reagents, substrates, peptides, and ligands 
NaHCO3, Na2HPO4, and C2H3O2 were purchased from VWR AMRESCO Life Sciences 
(Solon, OH). NaH2PO4 H2O was purchased from Mallinckrodt Chemical Works (St. 
Louis, MO). NaCl was purchased from Thermo Fisher (Waltham, MA). Tween 20 was 
purchased from Thermo Fisher (Waltham, MA). Neutravidin-horseradish peroxidase 
(HRP) was purchased from Thermo Fisher (Waltham, MA). SuperSignal ELISA Pico 
chemiluminescent substrate was purchased from Thermo Fisher (Waltham, MA). Ninety-
six well Microfluor 1 black and white plates were purchased from Greiner Bio-One North 
America, Inc. (Monroe, NC). The microplate luminometer (Fluoroskan Ascent FL) was 
obtained from Thermo Fisher (Waltham, MA). FAP-P (GNRQRWFV) corresponding to 
amino acid positions 269-276 of FAP-A; and control peptide (GVIGSANA) were used as 
test and control peptides, respectively (5). These peptides were synthesized and labelled 
with biotin at the N-terminus by GenScript (Piscataway, NJ). Bovine fibronectin (FN) 
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was obtained from Alfa Aesar (Ward Hill, MA) and bovine serum albumin (BSA) was 
obtained from VWR AMRESCO Life Sciences (Solon, OH).  
 
 
 
 
 
 
 
 
 
 
 
 
2.2 Enzyme-linked FN binding assay   
This assay was performed as depicted in Figure 2.1. A 96-well microtiter plate was 
coated with intact FN. Bovine serum albumin (BSA) was added to all wells to prevent 
non-specific binding. Plates were washed three times with PBST using a squirt bottle. 
Biotinylated FAP-P and biotinylated control peptides diluted in ANT buffer and BSA 
(control) were added to the appropriate wells and allowed to interact with FN (5). 
Fibronectin binding was detected by incubating the FN-coated wells with horseradish 
peroxidase (HRP) conjugated to Neutravidin (Thermo Fisher, Chicago, IL). After 
washing the plates as described above, the wells were incubated with SuperSignal Pico 
 
Figure 2.1: Enzyme-linked FN binding assay scheme 
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(Thermo Fisher), a chemiluminescent substrate for HRP-Neutravidin, for five minutes at 
room temperature as per manufacturer recommendation. Binding was detected using a 
microplate luminometer (Thermo Fisher) (5). Each probe was assayed in eight replicates 
in each of the three independent trials.  
 To describe the environment in which the interaction of FAP-P to FN in Johne’s 
disease manifests, the FN-binding assay was evaluated under the following parameters: 
1. Temperature effect on FN binding: the assay was performed at 37oC using 
ANT buffer (pH 6) as a peptide diluent and at room temperature (25oC) using 
PBST (pH 7.4) as a peptide diluent.  
2. Time effect on FN binding: FAP-P peptide and control peptide (at 0.2 µg/well, 
and 2.0 µg/well for each probe) were incubated at 30 minutes and 60 minutes in 
FN-coated wells.  
3. 96-well microtiter plate type effect on FN binding: Black 96-well microtiter 
plates and white 96-well microtiter plates were used for this luminescent assay to 
determine which plate obtains the best/higher signal-to-noise ratio.  
4. Specificity of FN binding: The assay was performed with half the microtiter 
plate coated with FN alone and the other half of the microtiter plate coated with 
BSA alone to determine if the FAP-P probe binds to FN only or to any readily 
available protein. 
5. Probe (FAP-P) concentration effect on FN binding: To determine if a dose 
effect existed between the FAP-P probe and FN, concentrations of 0.2 µg, 1.0 µg, 
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2.0 µg, and 4.0 µg of each probe were added to individual FN-coated wells and 
incubated at 37oC for 60 minutes. 
2.3 Statistics 
The statistical analyses Kruskal-Wallis H test, post hoc test and Student’s unpaired t 
test were performed using GraphPad Prism 4. 
 
Chapter 3: Results 
3.1 Specificity of FN binding 
BSA and all probes were incubated for 30 minutes at 37 oC in both FN-coated and 
BSA-coated wells. Luminescent signal from FN-coated wells probed with 2.0 µg FAP-P 
peptide was significantly greater than those probed with BSA and control peptides regardless 
of well coating (P ≤ 0.001) (Fig. 3.1). Each probe appeared to bind to FN-coated wells more 
readily than to BSA-coated wells with increasing background signal. Signal from the FAP-P 
probe was approximately 4-fold higher for FN-coated wells as compared to those coated with 
BSA. This indicates that probe concentration of 2 µg per well may be necessary to reveal 
specific binding of the FAP-P peptide to FN. 
3.2 Effect of temperature on FN binding 
FN binding assays in this investigation were conducted at 25oC and 37oC (Fig. 3.2) 
using FN-coated black 96-well microtiter plates with probes incubated for 30 minutes. 
Binding of FAP-P probe when used at 2.0 µg per well resulted in significantly higher signal 
than that of the control peptide at both 25oC and 37oC. However, the peak signal was greater 
at 37oC (P ≤ 0.01). These observations indicate that attachment of FAP-P to FN may be 
 21 
 
influenced by temperature over a short time frame (30 minutes). When FN-coated wells were 
probed at 25oC and 37oC with 2.0 µg FAP-P peptide were compared directly using Student’s 
T test, the signal to noise ratio at 37oC was nearly twice that observed at 25oC, and this effect 
was significant (P = 0.0003) (Fig 3.3). For this reason, subsequent experiments were 
conducted at 37oC.  
3.3 Effect of microtiter plate type on FN binding 
To assess the effects of microtiter plate color on the interaction of FAP-P with FN, the 
FN binding assay was conducted on both black and white 96-well microtiter plates with 
probes incubated for 30 minutes (Fig. 3.4).  
When incubated in white microtiter plates for 30 minutes, the amount of signal 
observed was approximately 8-fold higher than black microtiter plates. While FN-coated 
white microtiter plate wells probed with 2.0 µg FAP-P peptide yielded signal that was 
significantly higher than all treatments in black plates (P ≤ 0.001), the signal was not 
significantly different from those other wells probed with BSA or control peptides on FN-
coated white microtiter plates wells except for 2.0 µg control peptide.  
When probes were incubated with FN-coated wells using white microtiter plates for 
60 minutes (Fig 3.5), wells probed with 2.0 µg FAP-P peptide yielded significantly higher 
signal than those probed with all other probes (P ≤ 0.001) except for 2.0 µg FAP-P peptide at 
30 minutes. When FN-coated wells were probed at 30 minutes and 60 minutes with 2.0 µg 
FAP-P peptide were compared directly using Student’s T test, the signal to noise ratio at 60 
minutes was greater than that observed at 30 minutes, and this effect was significant (P < 
0.0001) (Fig 3.6). The specific signal level was increased approximately 3-fold over that 
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which was observed at 30 minutes of probing whereas the relative signal decreased. Thus, 
probing FN with FAP-P peptide for 60 minutes yielded the highest specific signal in white 
microtiter plates.  
3.4 FN binding dose response curve  
We next sought to determine if we could increase signal by increasing probe 
concentrations (Fig. 3.7). Increasing the concentrations of control peptide did not reveal a 
significant dose effect (R2 = 0.04) (Fig. 3.7). In contrast, the level of signal increased as the 
concentration of FAP-P peptides increased, to the extent that probe binding could be modeled 
using a second order polynomial expression (R2 = 0.72) (Fig. 3.7). Thus, the ELBA described 
herein can be used as a quantitative FN binding assay, as well as the presence or absence of 
binding. 
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Figure 3.1: Specificity of FN binding. FN binding assay was conducted on a black microtiter 96-
well plate. Half the plate was treated with intact FN and the other half was treated with bovine 
serum albumin (BSA) overnight. Control peptides and FAP-P peptides were incubated at 37oC for 
30 minutes in designated wells containing FN or BSA. The asterisk indicates a significant 
difference (P ≤ 0.001) between 2.0 µg FAP-P peptide in FN-coated wells and other treatments. 
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Figure 3.2: Effect of temperature on FN binding. Assays were conducted on a black 96-well 
microtiter plates. Designated wells were treated with intact FN overnight.  Control peptides and 
FAP-P peptides were incubated at 25oC or 37oC for 30 minutes in FN-coated wells. The asterisk 
indicates a significant difference (P ≤ 0.01) between 2.0 µg FAP-P peptide at 37oC and other 
treatments. 
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Figure 3.3. Binding of 2.0 µg FAP-P to FN-coated wells at 25oC and 37oC were compared by 
Student’s T test. The asterisk indicates a significant difference (P ≤ 0.0003) between 37oC and 
25oC.  
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Figure 3.4: Effect of microplate type on FN binding. This assay was conducted on a white 96-
well microtiter plate and a black 96-well microtiter plate and treated with intact FN overnight.  
Control peptides and FAP-P peptides were incubated in in FN-coated wells in either black or 
white microtiter plates at 37oC for 30 minutes. The asterisk indicates a significant difference (P ≤ 
0.001) between 2.0 µg FAP-P peptide in FN-coated wells in white microtiter plates and other 
treatments. 
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Figure 3.5: Effect of incubation time on FN binding. White 96-well microtiter plates were treated 
with intact FN overnight. Control peptides and FAP-P peptides were both incubated at 37oC for 30 
minutes or 60 minutes in FN-coated wells. An asterisk indicates a significant difference (P ≤ 0.001) 
between 2.0 µg FAP-P peptide in FN-coated wells incubated for 60 minutes and other treatments. 
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Figure 3.6. Binding of 2.0 µg FAP-P to FN at 30 minutes and 60 minutes incubation were 
compared by Student’s T test. The asterisk indicates a significant difference (P ≤ 0.0001) between 
60 minutes and 30 minutes. 
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Figure 3.7: FAP-P dose response curve on FN binding. Positive conditions of the FN binding 
assay were used to determine FAP-P dose effect of binding to FN. White 96-well microtiter 
plates were treated with intact FN overnight. Control peptides (CP) and FAP-P peptides at 0.2 
µg, 1.0 µg, 2.0 µg and 4.0 µg were incubated at 37oC for 60 minutes in FN-coated wells. CP is not 
significant at R2 = 0.04 and FAP-P is significant at R2=0.72.  
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Chapter 4: Discussion 
The long-term goal of our research plan is to reduce the incidence of Johne’s 
disease. The intermediate goal is to identify the region of FN that is recognized and 
bound by FAP-P, as this is not yet known (7). To achieve this, it is necessary to develop 
an effective assay to measure FAP-P binding to FN.  
As part of this optimization, we considered specificity of binding, temperature, 
time, microtiter plate type, and a probe dose response. A previous attempt to develop a 
colorimetric FN binding assay was hampered by very low signal-to-noise ratios (Breland 
and Secott, unpublished data). We therefore chose to use chemiluminescence because of 
the high sensitivity afforded by chemiluminescence detection (55, 56). In this 
investigation, we confirmed that FAP-P peptide binds specifically to intact FN. Lastly, 
we determined that by using white microtiter plates we were able to obtain increased FN 
binding signal as compared to that seen with black microtiter plates. Furthermore, we 
observed greater binding when probes were incubated at 37oC for 60 minutes. In 
addition, we were able to demonstrate that binding of FN by FAP-P increases with 
increased concentration of FAP-P peptides. Overall, we produced an enzyme-linked FN 
binding assay with a high signal-to-noise ratio and high sensitivity. 
A previous investigation reported that MAP invades intestinal tissue through the 
binding of the MAP protein FAP-P to fibronectin (FN). This binding is facilitated by 
integrins expressed on the luminal surface of M cells. The purpose of this investigation 
was to take an in vivo phenomenon such as FN binding by FAP-P and create an in vitro 
system where this interaction between FAP-P and FN can be more closely examined and 
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defined. To the best of our knowledge, this investigation is the first of its kind to measure 
FAP-P binding to FN.  
In this investigation, we determined that the FAP-P peptide binds specifically to 
FN. The apparent background signal for controls does not reflect non-specific probe 
binding, because the same results were realized with BSA which did not have a biotin 
label. Thus, the background signal more than likely reflects horseradish peroxidase 
(HRP)-Neutravidin binding to the ligands other than biotin. In addition, HRP-Neutravidin 
seemed to have bound FN-coated wells more readily than BSA-coated wells. Neutravidin 
is known to have fewer non-specific interactions than streptavidin and avidin (57). 
Avidin has a very high affinity for biotin and as such may bind to other proteins as biotin 
is found in mammalian cells (57). Streptavidin, on the other hand, has a peptide sequence 
(RYD) that resembles the binding sequence (RGD) of fibronectin (57). Consequently, 
this may have led to much of the background signal seen with this assay (57).  
Temperature influences the activity of horseradish peroxidase (HRP) (58). An 
investigation of HRP-antibody conjugate activity showed that the signal reaches its 
plateau relatively early at 37oC, whereas at 25 oC, the HRP signal continues to develop 
for several hours. Nevertheless, signal development occurred at the same rate for both 
temperatures (58). It is also possible that the higher temperature may have an influence 
on the conformation of the FAP-P peptide, which resulted in a stronger signal (58). 
Additionally, while the FAP-P peptide was positively charged (+2) and the 
control peptide was neutral (59), background signal was greater for FN-coated wells than 
for BSA-coated wells regardless of the probe used. At neutral pH (PBST), HRP-
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Neutravidin is slightly negative, with an isoelectric point (pI) = 6.3; FN is more negative 
(pI = 5.5-6) than HRP-Neutravidin and BSA very negatively charged (pI=4.8) (60). The 
differences in isoelectric points may explain why unspecific binding was observed in FN-
coated wells than in BSA-coated wells.  
This investigation determined that FN binding to FAP-P peptide was greater at 
37oC. This temperature is a commonly used temperature to conduct immunoassays 
relating to warm-blooded animals. We sought to observe binding of FAP-P to FN at this 
same temperature and at room temperature (25oC); however, that goal was confounded 
by a simultaneous change in pH of the peptide diluent buffers we used. At the onset of 
this investigation, the probes were diluted using PBST (pH 7.4) for the 25oC FN binding 
assay. However, it has been demonstrated that the binding of FN by MAP is activated by 
passage through an acidic environment in the ruminant digestive tract (7, 37). Secott, et 
al. found that FN binding by the intact organism is best observed when the organism is 
exposed to an acidic environment. As such, we proceeded to conduct our 37oC FN 
binding assay with probes diluted using ANT buffer (pH 6). Given that assays run at 
37oC in ANT buffer produced greater signal, this observation could support the 
conclusion that in vitro binding of FN by FAP-P, is influenced by pH.  
However, Secott et al noted that at neutral pH, the crucial FN-binding residues 
273RWFV276 within the FAP-P peptide have a net positive charge that would be unaltered 
in an acidic environment (7). Thus, the choice of probing buffer used in this assay may 
have had little effect on the binding of the probe. As such, what we observed is believed 
to be a temperature effect rather than a pH effect. Nevertheless, these experiments should 
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be repeated at 25oC using ANT buffer-treated probes. While increased temperature would 
be expected to increase the frequency of intermolecular collisions, it may also have 
improved the stability of the FN-FAP-P interaction. 
We realized higher FN binding signal with white microtiter plates than with black 
microtiter plates. Black objects tend to absorb all light wavelengths and reflect none, 
whereas white objects tend to reflect all light wavelengths and absorb none. For 
luminescence and fluorescence immunoassays, white and black 96-well microtiter plates 
respectively are usually recommended (61). However, phosphorescence (emission of 
light by a substance from stored energy) associated with the white microtiter plates can 
result in higher background signal (62). As a result, the choice of microtiter plate type 
should be based on experimental evidence. Our findings revealed that the use of white 
96-well microtiter plates resulted in a 10-fold increase in FN binding signal by the FAP-P 
peptide over that seen for black 96-well microtiter plates. Regardless of the plate type used, 
it is critical that luminescence assays be protected from light and white microtiter plate 
are more susceptible to light interference (61–64).  
For this study, we attempted to increase the signal by increasing probe incubation 
time. We detected greater binding between FAP-P and FN with increased (60 minutes) 
probing time as compared to that seen at 30 minutes. The observation that a doubling of 
the binding time resulted in a nearly 3-fold increase in signal suggests that the FAP-P-FN 
interaction is not simply a first order reaction. We have not established the time necessary 
for FAP-P-FN binding to reach equilibrium (65). Additional experiments using longer 
probing times will be necessary to optimize the timing of this step. 
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Ratliff et al established that in vitro binding of Mycobacterium bovis (BCG) to 
FN-coated surfaces occurred in a dose-dependent manner with purified fibronectin (54). 
We sought to determine the concentration of test peptide required to detect a positive FN 
binding response in Johne’s disease. Increased FAP-P peptide concentration lead to 
increased FN binding. We did not manipulate the coating protein concentration. As such, 
we showed that FAP-P binds to FN in a dose-dependent manner. Therefore, this FN 
binding assay could be used in a quantitative format. In addition, we have not determined 
the maximum dose of the FAP-P peptide to bind intact FN. Thus, we need to determine 
the linear range of this FN binding assay. 
One of the difficulties encountered in this investigation involved the source of our 
soluble fibronectin. The FN solutions used in this investigation were purchased several 
times from three suppliers. This was due to the protein solution becoming unstable and 
polymerizing in storage, preventing even distribution into microplate wells. 
Consequently, the results of our assay varied in earlier trials. The last batch was 
lyophilized in Tris buffer. After reconstitution in sterile water according to manufacturer 
instructions, the solution had to be stored for one week at 4oC to be completely dissolved. 
We then stored this in single use aliquots at -20 oC. This approach enabled us to realize 
more consistent results.  
We used synthesized FAP-P peptides to probe FN instead of using intact MAP 
cells in culture. The reason for avoiding intact MAP was to eliminate problems arising 
from MAP culture contamination. Further, the use of intact MAP would have meant that 
MAP-FN interaction would not be limited to FAP-P, as MAP expresses several FN 
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binding proteins (7). Finally, due to the slow-growing nature of MAP, it would have 
taken considerably longer to conduct this series of experiments. 
The outcome of this investigation will allow for the FN region that is recognized 
and bound by FAP-P to be identified. To do so, researchers would have to first conduct 
proteolytic cleavage of FN, purify the FN fragments by electroelution, coat white 
microtiter plates with purified FN fragments, and finally probe with biotinylated FAP-P 
peptide to identify the region of FN to which FAP-P binds. 
 The FN binding assay could be further refined by examining the effects of 
conjugate concentration on assay signal and specificity. We could also incorporate a 
second blocking step between probing and addition of conjugate, to further reduce 
background noise.  
 Another goal enabled by this research will be to determine if FAP-P recognizes a 
linear epitope of fibronectin rather than a conformational epitope of fibronectin. This 
information could lead to the synthesis of a peptide/protein that could be added to 
colostrum and used as a milk replacer for calves. This synthesized peptide would behave 
as a FAP-P competitor to minimize binding of MAP to fibronectin.  
 The data presented in this thesis described the optimization of an assay to detect 
FN binding using a chemiluminescence probe which will be useful for identifying the 
binding domain on FN by FAP-P. This is an essential component in the design of a 
peptide to inhibit MAP binding to bovine intestinal epithelial cells. As such, the results of 
this investigation will likely lead to a reduction in the incidence of Johne’s disease, 
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increasing the profitability of dairy farming while preserving the supply of safe, 
affordable dairy products for the consumers. 
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